IRIS - Res&Arch Institutional Research Information System - Research & Archive

CRINO', Lucio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.224
EU - Europa 2.592
AS - Asia 1.187
SA - Sud America 223
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 7.239
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.198
IE - Irlanda 598
SG - Singapore 544
IT - Italia 401
SE - Svezia 388
RU - Federazione Russa 355
UA - Ucraina 272
HK - Hong Kong 260
BR - Brasile 214
FI - Finlandia 188
VN - Vietnam 173
DE - Germania 149
CN - Cina 116
FR - Francia 62
GB - Regno Unito 56
KR - Corea 36
AT - Austria 24
CH - Svizzera 23
CA - Canada 20
NL - Olanda 14
PL - Polonia 14
IN - India 13
RO - Romania 12
BE - Belgio 9
CZ - Repubblica Ceca 9
GR - Grecia 8
TR - Turchia 8
UZ - Uzbekistan 7
BD - Bangladesh 6
LB - Libano 6
AR - Argentina 5
ZA - Sudafrica 5
MX - Messico 4
LT - Lituania 3
IL - Israele 2
IQ - Iraq 2
JP - Giappone 2
KZ - Kazakistan 2
MA - Marocco 2
NG - Nigeria 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
CO - Colombia 1
CR - Costa Rica 1
DK - Danimarca 1
EG - Egitto 1
HU - Ungheria 1
IR - Iran 1
KW - Kuwait 1
MD - Moldavia 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 7.239
Salva come PNG Salva come JPEG
Città #
Chandler 628
Dublin 598
Singapore 350
San Mateo 345
Hong Kong 260
Boardman 225
Dong Ket 169
Santa Clara 161
Andover 146
Medford 145
Princeton 143
Jacksonville 134
Perugia 132
Altamura 129
Lawrence 123
Ann Arbor 107
Wilmington 98
Moscow 84
Beijing 61
Saint Petersburg 45
Munich 41
Helsinki 37
Seoul 36
Norwalk 31
San Paolo di Civitate 28
Los Angeles 23
Des Moines 21
Ashburn 19
São Paulo 19
Redwood City 16
Falls Church 14
Woodbridge 13
Bucharest 12
New York 12
Turku 12
Lausanne 11
Nuremberg 11
Rio de Janeiro 11
Brussels 9
Dearborn 9
Brooklyn 8
Den Haag 8
Falkenstein 8
The Dalles 8
Vienna 8
Auburn Hills 7
Chicago 7
San Francisco 7
Lappeenranta 6
Simi Valley 6
Curitiba 5
London 5
Ottawa 5
Shanghai 5
Warsaw 5
Arezzo 4
Belo Horizonte 4
Boston 4
Campinas 4
Columbus 4
Guarulhos 4
Redmond 4
San Diego 4
Tappahannock 4
Toronto 4
Brasília 3
Campo Grande 3
Chengdu 3
Chennai 3
Costa Mesa 3
Dallas 3
Foligno 3
Frankfurt Am Main 3
Goiânia 3
Guangzhou 3
Hortolândia 3
Houston 3
Izmir 3
Johannesburg 3
Manassas 3
Marsciano 3
Montreal 3
Nanjing 3
Nürnberg 3
Osasco 3
Rome 3
Santo André 3
Stockholm 3
Torgiano 3
Annapolis 2
Aparecida de Goiânia 2
Araras 2
Asso 2
Betim 2
Brno 2
Campos dos Goytacazes 2
Capitão Poço 2
Charlotte 2
Cleveland 2
Cusano Milanino 2
Totale 4.700
Salva come PNG Salva come JPEG
Nome #
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study 109
Significato prognostico dell’espressione immunoistochimica di Insulin like growth facor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 108
Prognostic Role of Erbb Family Receptors, Myc and Mitogen-activated Protein Kinase (mapk) In Patients With Early-stage Non Small-cell Lung Cancer 101
Afatinib In Egfr Mutant Non-small-cell Lung Cancer Patients With Acquired Resistance To Reversible Egfr-tkis 93
P-126 * PROGNOSTIC SIGNIFICANCE OF MYC AND HUMAN TELOMERASE GENE AMPLIFICATION IN SURGICALLY TREATED EARLY STAGE NON-SMALL CELL LUNG CANCER 92
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. 88
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer 88
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 87
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 81
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free servival in resected non-small-cell lung cancer patients. 79
Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma. 77
An approach for optimally extending mathematical models of signaling networks using omics data 77
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer 77
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer 76
Phase II study of weekly paclitaxel and trastuzumab in anthracycline and taxane pretreated patients with HER2 overexpressing metatastatic breast cancer 74
Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids 73
A Hybrid Model of Nucleotide Excision Repair in Neoplastic diseases and in vitro Experiments 73
Combined chemotherapeutic and radiotherapeutic treatment of limited pulmonary microcytoma 73
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort 72
Non-coding RNAs in lung cancer 71
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. 71
A machine learning approach applied to Reverse Phase Protein Microarray data for pathways activation mapping of KRAS wild type and mutated adenocarcinomas of the lung 70
Acute myeloblastic leukemia after adjuvant chemo¬therapy with melphalan in breast cancer. Case report with cytogenetic analysis. 69
Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. 68
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 68
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? 67
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology 67
Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment 66
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer 66
Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer Safety of Avastin in Lung trial (MO19390) 66
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease 65
Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment 65
Pathway Activation Mapping of Kras Wild Type and Mutated Adenocarcinomas of the Lung: New Implications For Patient Stratification For Map Kinase Pathway Inhibition 65
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial 65
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. 64
Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. 64
Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer 64
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 63
Carcinomi mammari "triple negative": studio dei fattori prognostici e predittivi. 62
Carcinomi mammari “triple negative”: studio dei fattori prognostici e predittivi 62
Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). 62
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 62
Long-term survival and prognostic factors in neuroendocrine tumors: Results from a large multicenter study 61
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 61
Espressione dei recettori HER nei carcinomi non a piccole cellule del polmone 60
Systems biology in personalized medicine in oncology: A case study in non-small cell lung cancer 59
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study 59
Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer Summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop 59
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 59
A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. 58
EGFR, KRAS, PIK3CA mutations and response to tyrosine kinase inhibitors (TKIs) in advanced NSCLC patients. 57
MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non-small Cell Lung Cancer 57
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients 57
Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. 57
Microinvasive breast cancer: clinical pathological characteristics and treatment. Experience from two institutions 56
Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology (vol 30, pg 142, 2012) 56
A prospective study on survival in cancer patients with and without venous thromboembolism. 56
Mutational analysis of KRAS, BRAF, and p53 genes in borderline and malignant epithelial ovarian tumors. 55
Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors 55
Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study 55
Dynamic network topologies analysis in proteomics data of NSCLC cell lines using a new pipeline based on machine learning tools 55
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients. 54
ERCC1 expression in triple negative breast carcinoma: the paradox revisited. 53
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors 53
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 53
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 53
Carcinomi mammari “tripli negativi”: significato biologico e prognostico dell’espressione di ERCC1. 52
ERCC1 and RRM1 mRNA expression in resected patients with non-small-cell-lung-cancer (NSCLC). (A study of the Perugia multidisciplinary team for thoracic tumors) 52
Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology 52
ALK Rearrangement Testing by FISH Analysis in Non-Small-Cell Lung Cancer Patients Results of the First Italian External Quality Assurance Scheme 52
High coexpression of both insulin-like growth factor receptor 1 (igfr-1) and epidermal growth factor receptor (egfr) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients 51
Effect of genetic polymorphisms (GP) on toxicity and survival in early breast cancer (EBC) patients (PTS) treated with adjuvant chemotherapy (CT) 51
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non-Small Cell Lung Cancer Patients 51
An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy 51
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 51
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 51
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up 51
Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection? 51
Lack of Accuracy of Circulating Chromogranin A in the Preoperative Diagnosis of Lung Neuroendocrine Tumors 49
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 49
Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation. 48
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 48
PD-L1 quantification across tumor types using the reverse phase protein microarray: Implications for precision medicine 48
Significato prognostico dell'espressione immunoistochimica di insulin like growth factor receptor 1 (IGFR-1) ed epidermal growth factor receptor (EGFR) nei carcinomi non a piccole cellule del polmone (NSCLC). 47
Mir-99a/let7c/mir-125b Signature To Predict Sensitivity To Anti-egfr Monoclonal Antibodies In Metastatic Colorectal Cancer (mcrc) 47
Frequency and clinical correlations of epidermal growth factor receptor (EGFR) mutations in a large cohort of Italian non-small cell lung cancer (NSCLC) patients (pts) within the EGFR FASTnet program. 47
Clinical significances of ErbB family receptors, Myc, and mitogen-activated protein kinase (MAPK) in patients with early-stage non-small cell lung cancer. 47
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 46
Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. 46
MYC and human telomerase (TERC) gene copy number gain in resected non-small cell lung cancer (NSCLC) 45
Robustness of complex feedback systems: application to oncological biochemical networks 44
Emerging drugs for small cell lung cancer - an update 44
Risk Stratification Model For Resected Squamous Cell Lung Cancer (r-sqlc) Patients (pts) According To Clinical and Pathological Factors 44
INSULIN-LIKE GROWTH FACTOR RECEPTOR 1 (IGF1R) AND EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFICATION AND EXPRESSION IN SURGICALLY RESECTED NSCLC 44
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis 44
Increased levels of circulating DNA in patients with connective tissue diseases: a possible marker of disease activity in Sjögren’s syndrome 42
Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non-Small-Cell Lung Cancer A Phase-II Study 42
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study 42
First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer 42
Management of Italian Patients With Advanced Non-Small-Cell Lung Cancer After Second-Line Treatment: Results of the Longitudinal Phase of the LIFE Observational Study 41
Totale 6.080
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.591
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.591
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202024 0 0 0 0 0 0 0 0 0 0 0 24
2020/2021975 4 36 50 39 319 79 48 5 99 41 64 191
2021/20221.152 29 237 12 75 19 11 7 446 14 12 119 171
2022/20232.061 149 394 16 180 157 206 0 96 772 1 69 21
2023/2024630 44 75 51 16 6 1 122 7 47 29 112 120
2024/20251.702 43 168 100 47 270 48 32 122 351 114 236 171
Totale 7.525